Von der Pathophysiologie und Prävention des ovariellen Überstimulationssyndroms (OHSS) bis zur stadiengerechten Therapie

Zusammenfassung

Das schwere ovarielle Überstimulationssyndrom (OHSS) kompliziert 0,3 - 5 % der Zyklen kontrollierter ovarieller Stimulation im Rahmen assistierter reproduktiver Techniken (ART). Obwohl die Ursachen des OHSS nicht endgültig geklärt sind, löst das zur Ovulationsinduktion gegebene HCG oder die endogene HCG-Produktion beim Eintritt einer Schwangerschaft das OHSS aus. Es erfolgt eine vermehrte Neoangiogenese und erhöhte Kapillarpermeabilität im Bereich der Ovarien, so dass es lokal zu einem vermehrten Flüssigkeitsübertritt aus den Ovarien in die Bauchhöhle als Aszites kommt, beim schweren OHSS verläuft die Erkrankung durch die erhöhte Gefäßpermeabilität meist systemisch. Die wichtigsten Faktoren, die auf zellulärer Ebene für das Entstehen eines OHSS verantwortlich gemacht werden, sind das Angiotensin-Renin-Aldosteron-System, Zytokine (IL-1, IL-2, IL-6, IL-8), der Tumornekrosefaktor alpha (TNF-α) und in zentraler Rolle der Vascular endothelial growth factor (VEGF). Da in supprimierten Stimulationszyklen die Ovulationsinduktion derzeit nur mit HCG ausgelöst werden kann, lässt sich das OHSS trotz verschiedener Ansätze der Prävention nicht komplett vermeiden. Deshalb möchten wir in dieser Arbeit eine Übersicht der stadienadaptierten Therapie vorstellen.

Abstract

Severe ovarian hyperstimulation syndrome (OHSS) complicates 0.3 - 5 % of controlled ovarian stimulation cycles for assisted reproductive techniques (ART). Although the reasons for OHSS still remain enigmatic, HCG either applicated for ovulation induction or produced by the trophoblast is the most important trigger for developing OHSS. Enhanced neoangiogenesis and capillary permeability in the ovaries cause a third space fluid shift which locally results in ascites or pleural effusion reflecting systemic severe OHSS. The most important factors which are involved in the development of OHSS on the cellular level are the angiotensin-renin-aldosteron-system, cytokines (IL-1, IL-2, IL-6, IL-8), tumor necrosis factor alpha (TNF-α) and of central importance vascular endothelial growth factor (VEGF). As OHSS cannot completely be prevented in down-regulated stimulation cycles, this article can be regarded as a guideline for adequate therapy strategies depending upon the grade of OHSS.

OHSS - Prävention - Therapie - Kapillarpermeabilität - Zytokine

OHSS - Prevention - Therapy - Capillary permeability - Cytokines

Literatur

• 1 Aboulghar M, Evers J H, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome.  Cochrane Database Syst Rev. 2000;  2 CD001302
• 2 Abramov Y, Schenker J G, Lewin A. et al . Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome.  Hum Reprod. 1996;  11 1381-1386
• 3 Abramov Y, Barak V, Nisman B, Schenker J G. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.  Fertil Steril. 1997;  67 261-265
• 4 al-Shawaf T, Zosmer A, Hussain A, Tozer A, Panay N, Wilson C, Lower A M, Grudzinskas J G. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified “coasting” strategy based on ultrasound for identification of high-risk patients.  Hum Reprod. 2001;  16 24-30
• 5 Araujo E, Bernardini L, Frederick J L. Prospective randomized comparison of human chorionic gonadotrophin versus intramuscular progesterone for luteal-phase support in assisted reproduction.  J Assist Reprod Genet. 1994;  11 74-78
• 6 Blumenfeld Z, Lang N, Amit A. et al . Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.  Fertil Steril. 1994;  62 456-460
• 7 Chen C D, Wu M Y, Yang J H. et al . Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.  Fertil Steril. 1998;  68 287-291
• 8 Claman P, Domingo M, Leader A. et al . Luteal-phase support in an in-vitro fertilization program using gonadotropin-releasing hormone analogue (GnRHa) before superovulation.  Hum Reprod. 1992;  7 487-491
• 9 Der-Chen C, Fu-Chen H, Fen-Lu H. et al . Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome.  Hum Reprod. 2000;  15 1037-1042
• 10 Egbase P E, Al-Sharhan M, Grudzinskas J G. Early unilateral follicular aspiration compared to coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study.  Hum Reprod. 1999;  14 1421-1425
• 11 Egbase P E, Makhseed M, Al Sharhan M, Grudzinskas J G. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotropin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro-fertilization: a prospective randomised study.  Hum Reprod. 1997;  12 2603-2606
• 12 Egbase P E, Al-Sharhan M, Berlingieri P, Grudzinskas J G. Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment.  Hum Reprod. 2000;  15 2082-2086
• 13 Elchalal U, Schenker J G. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas.  Hum Reprod. 1997;  12 1129-1137
• 14 Gerris J, De-Vits A, Joostens M, Van-Royen E. Triggering of ovulation-induction in human menopausal gonadotropin-stimulated cycles: comparison between intravenously administered gonadotropin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotropin (10, 000 IU).  Hum Reprod. 1995;  10 56-62
• 15 Felberbaum R, Reissmann T, Küpker W, Diedrich K. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonist (Cetrorelix) in women with tubal infertility.  Eur J Obstet Gynecol Reprod Biol. 1995;  61 151-155
• 16 Ferraretti A P, Gianaroli L, Magli C, Fortini D, Selman H A, Feliciani E. Elective cryopreservation of all pronucleate embryos in woman at risk of ovarian hyperstimulation syndrome: efficiency and safety.  Hum Reprod. 1999;  14 1457-1460
• 17 Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Capsi E. Ovarian hyperstimulation syndrome: an update review.  Obstet Gynecol. 1989;  44 430-440
• 18 Hack C E, DeGroot E R, Felt-Bersma R JF. Increased plasma levels of interleukin-6 in sepsis.  Blood. 1989;  74 1704-1710
• 19 Haning R V, Srawn E Y, Nolten W E. Pathophysiology of the ovarian hyperstimulation syndrome.  Obstet Gynecol. 1985;  66 882-889
• 20 Jäger W, Wildt L, Lang N. Ovarian hyperstimulation syndrome. Hafez ESE Assisted Human Reproductive Technology. 1991: 61-75
• 21 Kodama H, Fukuda J, Karube H, Matsui T, Shimizu Y, Tanaka T. Characteristic of blood hemostatic markers in a patient of ovarian hyperstimulation syndrome who actually developed thromboembolism.  Fertil Steril. 1995;  64 1207-1209
• 22 Keck C, Neulen J, Breckwoldt M. Das ovarielle Hyperstimulationssyndrom.  Geburtsh Frauenheilk. 1994;  54 315-320
• 23 Kissler S, Neidhardt B, Siebzehnruebl E, Schmitt H, Tschaikowsky K, Wildt L. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation sydrome - a case report.  Eur J Obstet Gynecol. 2001;  99 131-134
• 24 Knox G E. Antihistamine blockade of the ovarian hyperstimulation syndrome.  Am J Obstet Gynecol. 1974;  118 992-994
• 25 Krasnow J S, Berga S L, Gusick D S. et al . Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome - a preliminary report.  Fertil Steril. 1996;  65 552-555
• 26 Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of GnRH-analogues and HCG for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case control-study.  Hum Reprod. 1996;  11 1399-1402
• 27 Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF.  Acta Obstet Gynaecol Scand. 2001;  80 in press
• 28 Ludwig M, Felberbaum R E, Devroey P, Albano C, Riethmüller-Winzen H, Schüler A, Engel J, Diedrich K. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix in controlled ovarian stimulation for assisted reproduction.  Arch Gynecol Obstet. 2000;  264 29-32
• 29 Ludwig M, Finas A, Katalinic A, Strik D, Kowalcek I, Schwartz P, Felberbaum R, Kupker W, Schopper B, Al-Hasani S, Diedrich K. Prospective, randomized study to evaluate the success rates using HCG, vaginal progesterone or a combination of both for luteal support.  Acta Obstet Gynaecol Scand. 2001;  80 574-582
• 30 Ludwig M, Bauer O, Lopens A, Jelkmann W, Diedrich K. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome.  Hum Reprod. 1998;  13 30-32
• 31 Meirow D, Schenker J G, Rosler A. Ovarian hyperstimulation syndrome with low oestradiol in non-classic 17 alpha-hydroxylase, 17, 20-lyase deficiency: What is the role of oestrogens?.  Hum Reprod. 1996;  11 2119-2121
• 32 Morris R S, Wong I L, Kirkman E. et al . Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome.  Hum Reprod. 1995;  10 1355-1358
• 33 Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, Serr D M. et al . Thromboembolic phenomena after ovarian stimulation with human gonadotrophins.  Lancet. 1965;  2 1213-1215
• 34 Navot D, Margalioth E J, Laufer N. Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome.  Fertil Steril. 1987;  48 57-61
• 35 Neulen J, Yan Z, Raczek S. et al . Human chorionic gonadotropin-dependant expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.  J Clin Endocrinol Metabol. 1995;  80 1967-1971
• 36 Neulen J. Das ovarielle Überstimulationssyndrom.  Geburtsh Frauenheilk. 2001;  61 XLI-XLIII
• 37 Neulen J. Reproduktionsmedizin. Keck C, Neulen J, Breckwoldt M Endokrinologie, Reproduktionsmedizin, Andrologie. 1. Aufl. Stuttgart; Thieme 1997: 132-135
• 38 Okusawa S, Gelfand J, AIkefima T. et al . Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.  J Clin Invest. 1988;  81 1162-1172
• 39 Olivennes F. Induction of final oocyte maturation by a single dose of GnRH agonist after Ganirelix treatment.  Gynecol Endocrinol. 2001;  15 (Suppl 1) 7
• 40 Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotrophin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH-antagonist.  Fertil Steril. 1996;  66 151-153
• 41 Quenaan J TJ, Veeck L L, Toner J P, Oehninger S, Muasher S J. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers.  Hum Reprod. 1997;  12 1573-1576
• 42 Ravindranath N, Little-Ihrig L, Phillips H S. Vascular endothelial growth factor mRNA expression in the primate ovary in relation to follicular growth and corpus luteum function.  Endocrinol. 2001;  2065 254-260
• 43 Rimington M R, Walker S M, Shaw R W. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilisation treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries.  Hum Reprod. 1997;  12 1443-1447
• 44 Schenker J G, Polishuk W Z. Ovarian hyperstimulation syndrome.  Obstet Gynecol. 1975;  46 23-28
• 45 Schenker J G, Polishuk W Z. The role of prostaglandins in ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 1976;  6 47-52
• 46 Schwartz M, Jewelewicz R. The use of gonadotropins for induction of ovulation.  Fertil Steril. 1981;  35 3-12
• 47 Senger D R, Galli S J, Dvorak A M. et al . Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.  Science. 1983;  219 983-985
• 48 Shaker A G, Zosmer A, Dean N, Bekir J S, Jacobs H S, Tan S L. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome.  Fertil Steril. 1996;  65 992-996
• 49 Sher G, Zouves C, Feinman M, Maassarani G. “Prolonged coasting”: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilisation.  Hum Reprod. 1995;  10 3107-3109
• 50 Thaler I, Yoffe N, Kaftory J K, Brandes J M. Treatment of ovarian hyperstimulation syndrome: the physiological basis for a modified approach.  Fertil Steril. 1981;  36 110-113
• 51 Watson J M, Sensintaffar F L, Berek J S, Martinez-Masa O. Constitutive production of IL-6 by ovarian cancer cell-lines and by primary ovarian tumor cultures.  Cancer Res. 1990;  50 6959-6965
• 52 World Health Organization . Agents stimulating gonadal function in humans.  WHO Techn Rep Series. 1973;  514
• 53 Zaides I, Friedman M, Lindenbaum E S. et al . Serotonin and the ovarian hyperstimulation syndrome.  Eur J Obstet Gynecol Reprod Biol. 1983;  15 55-61